For Health Care Professionals Outside the US

 
 
 

Extend PFS in your patients with relapsed and/or refractory multiple myeloma1

In a subgroup analysis, adding FARYDAK® (panobinostat) regimen improved median progression-free survival (PFS) by 7.8 months1

FVD regimen demonstrated a 7.8 month difference in median PFS vs placebo/bortezomib (BTZ)/dexamethasone (dex) (12.5 vs 4.7 months) in patients who received at least 2 prior regimens, including BTZ and an immunomodulatory drug (IMiD).1

FARYDAK is the first HDAC inhibitor approved in multiple myeloma.1

See how FARYDAK regimen helped deepen response in the PANORAMA 1 pivotal trial 

Reference:

  1. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; August 2015.

Is FARYDAK right for your patients? Meet John

The link you have chosen leads to a site maintained by a third party over whom Novartis has no control. As such, Novartis makes no representation as to the accuracy or any other aspect of the information on this site.